Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and research laboratories worldwide, specifically in the fields of cytology, cytogenetics, and pathology. The company's extensive product lineup includes: Accord: A semi-automated fluorescent imaging and analysis workbench microscope station. Accord Plus: An automatic fluorescent imaging system capable of real-time scanning, analysis, and sorting of diverse FISH (Fluorescence In Situ Hybridization) samples. Allegro Plus: Another automatic fluorescent imaging system engineered to pinpoint various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. DUET-3: An imaging and analysis platform featuring an automated barcode reader, which streamlines the processing of multiple test types within a single scan batch. DeNovo: An automated scanning system dedicated to the precise detection, analysis, and characterization of circulating tumor cells found in peripheral blood. Solo Workstation & Solo Touch Workstation: These are offline and standalone workstations, respectively, providing advanced tools for reviewing and analyzing test results remotely from the microscope. SoloWeb: A comprehensive web-based solution that enables remote analysis, reporting, and expert consultation on cases scanned using Bio-View's systems. Furthermore, Bio-View Ltd has established a strategic partnership with ANGLE plc to jointly develop a liquid biopsy circulating tumor cell HER2 assay, specifically targeting breast cancer.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is undervalued on P/FCF.